Valion Bio, Inc.

VBIO Healthcare Biotechnology

Valion Bio, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $780,000.00, down 33.7% from fiscal 2023. In the quarter to June 2026, revenue grew 15.9%, EPS was flat and free cash flow fell 189.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

1.17 0.06 −4.88%
Market cap
$2.4M
P/E
0.0×
Fwd P/E
0.0×
Dividend yield
—
F-score
3/9
Altman Z
−21.96
Beneish M
48.80
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
Piotroski F-Score

+8 more TTM periods

3 — — —
ROE
(178.21%) (93.69%) (198.48%) (489.30%)
ROA
(156.02%) (52.63%) (66.64%) (104.96%)
ROIC
(152.85%) (26.95%) (41.17%) (61.01%)
Return on Tangible Assets
(241.07%) (36.22%) (74.89%) (153.07%)
Average Days of Receivables
14.39 — — —
Free Cash Flow per Share
(115.34) (164.07) (96.84) (108.54)
Free Cash Flow
(6.09) (7.58) (11.17) (14.67)
Other line items

Show all line items

Columns are period end dates